Which has preferable valuation and earnings, AVLN or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A -$22.81 N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is AVLN or BLTE more profitable?

Avalyn Pharma's return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Belite Bio N/A -11.84% -11.62%

Does the media refer more to AVLN or BLTE?

In the previous week, Avalyn Pharma and Avalyn Pharma both had 2 articles in the media. Avalyn Pharma's average media sentiment score of 0.93 equaled Belite Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVLN or LQDA?

In the previous week, Liquidia had 5 more articles in the media than Avalyn Pharma. MarketBeat recorded 7 mentions for Liquidia and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.93 beat Liquidia's score of 0.88 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, DFTX or AVLN?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Avalyn Pharma N/A N/A N/A -$22.81 N/A

Is DFTX or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Avalyn Pharma N/A N/A N/A

Does the media refer more to DFTX or AVLN?

In the previous week, Definium Therapeutics had 3 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Definium Therapeutics and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.93 beat Definium Therapeutics' score of 0.76 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or AVLN?

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.93 beat Amneal Pharmaceuticals' score of 0.71 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, AVLN or MANE?

Veradermics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A -$22.81 N/A Veradermics N/A N/A -$70M -$1.90 N/A

Is AVLN or MANE more profitable?

Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Veradermics N/A N/A N/A

Does the media prefer AVLN or MANE?

In the previous week, Veradermics had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Veradermics and 2 mentions for Avalyn Pharma. Veradermics' average media sentiment score of 0.94 beat Avalyn Pharma's score of 0.93 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Avalyn Pharma (AVLN) Competitors

$34.69 -1.82 (-4.98%)

As of 08/28/2026 04:00 PM Eastern

Compare

AVLN vs. BLTE, LQDA, DFTX, AMRX, and MANE

Should you buy Avalyn Pharma stock or one of its competitors? Avalyn Pharma's main competitors and comparable companies include Belite Bio (BLTE), Liquidia (LQDA), Definium Therapeutics (DFTX), Amneal Pharmaceuticals (AMRX), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Avalyn Pharma compare to Belite Bio?

Avalyn Pharma (NASDAQ:AVLN) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Avalyn Pharma's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Belite Bio	N/A	-11.84%	-11.62%

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Belite Bio is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Avalyn Pharma presently has a consensus target price of $60.00, indicating a potential upside of 72.96%. Belite Bio has a consensus target price of $205.80, indicating a potential upside of 35.64%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Avalyn Pharma is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Avalyn Pharma and Avalyn Pharma both had 2 articles in the media. Avalyn Pharma's average media sentiment score of 0.93 equaled Belite Bio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Avalyn Pharma beats Belite Bio on 6 of the 10 factors compared between the two stocks.

How does Avalyn Pharma compare to Liquidia?

Avalyn Pharma (NASDAQ:AVLN) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Avalyn Pharma has higher earnings, but lower revenue than Liquidia. Avalyn Pharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
Liquidia	$450.91M	13.44	-$68.92M	$1.37	49.41

In the previous week, Liquidia had 5 more articles in the media than Avalyn Pharma. MarketBeat recorded 7 mentions for Liquidia and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.93 beat Liquidia's score of 0.88 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a net margin of 30.74% compared to Avalyn Pharma's net margin of 0.00%. Liquidia's return on equity of 149.65% beat Avalyn Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Liquidia	30.74%	149.65%	36.30%

Avalyn Pharma presently has a consensus target price of $60.00, suggesting a potential upside of 72.96%. Liquidia has a consensus target price of $98.08, suggesting a potential upside of 44.90%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Avalyn Pharma is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

64.5% of Liquidia shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Liquidia beats Avalyn Pharma on 10 of the 14 factors compared between the two stocks.

How does Avalyn Pharma compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Avalyn Pharma (NASDAQ:AVLN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Definium Therapeutics presently has a consensus price target of $63.00, indicating a potential upside of 53.73%. Avalyn Pharma has a consensus price target of $60.00, indicating a potential upside of 72.96%. Given Avalyn Pharma's higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Definium Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

In the previous week, Definium Therapeutics had 3 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Definium Therapeutics and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.93 beat Definium Therapeutics' score of 0.76 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Avalyn Pharma	N/A	N/A	N/A

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Definium Therapeutics beats Avalyn Pharma on 6 of the 11 factors compared between the two stocks.

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Avalyn Pharma (NASDAQ:AVLN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Amneal Pharmaceuticals has higher revenue and earnings than Avalyn Pharma. Avalyn Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.86	$72.06M	$0.49	35.80
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 2 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.93 beat Amneal Pharmaceuticals' score of 0.71 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a net margin of 5.05% compared to Avalyn Pharma's net margin of 0.00%. Avalyn Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Avalyn Pharma	N/A	N/A	N/A

Amneal Pharmaceuticals presently has a consensus price target of $19.00, indicating a potential upside of 8.32%. Avalyn Pharma has a consensus price target of $60.00, indicating a potential upside of 72.96%. Given Avalyn Pharma's higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats Avalyn Pharma on 10 of the 14 factors compared between the two stocks.

How does Avalyn Pharma compare to Veradermics?

Avalyn Pharma (NASDAQ:AVLN) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Avalyn Pharma presently has a consensus price target of $60.00, indicating a potential upside of 72.96%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 56.70%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Avalyn Pharma is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Veradermics had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Veradermics and 2 mentions for Avalyn Pharma. Veradermics' average media sentiment score of 0.94 beat Avalyn Pharma's score of 0.93 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Veradermics	N/A	N/A	N/A

Summary

Avalyn Pharma and Veradermics tied by winning 4 of the 8 factors compared between the two stocks.

Get Avalyn Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVLN vs. The Competition

Export

Metric	Avalyn Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.54B	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-1.52	787.65	273.16	25.45
Price / Sales	N/A	792.29	592.32	71.88
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	3.86	11.97	12.98	6.14
Net Income	N/A	$2.83B	$3.48B	$348.86M
7 Day Performance	-9.59%	0.39%	0.13%	-0.80%
1 Month Performance	18.36%	5.34%	7.08%	4.13%
1 Year Performance	N/A	6.05%	24.67%	15.17%

Avalyn Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVLN Avalyn Pharma	2.4889 of 5 stars	$34.69 -5.0%	$60.00 +73.0%	N/A	$1.54B	N/A	N/A	51
BLTE Belite Bio	3.1548 of 5 stars	$151.72 -3.4%	$205.80 +35.6%	+140.7%	$6.29B	N/A	N/A	10
LQDA Liquidia	4.2002 of 5 stars	$67.69 -3.2%	$98.08 +44.9%	+144.5%	$6.26B	$158.32M	49.41	50	Insider Trade
DFTX Definium Therapeutics	3.7309 of 5 stars	$40.98 -6.5%	$63.00 +53.7%	+361.5%	$5.89B	N/A	N/A	40
AMRX Amneal Pharmaceuticals	3.4762 of 5 stars	$17.54 -2.6%	$19.00 +8.3%	+83.5%	$5.75B	$3.02B	35.80	8,500	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVLN) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalyn Pharma (AVLN) Competitors

AVLN vs. BLTE, LQDA, DFTX, AMRX, and MANE

How does Avalyn Pharma compare to Belite Bio?

Summary

How does Avalyn Pharma compare to Liquidia?

Summary

How does Avalyn Pharma compare to Definium Therapeutics?

Summary

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Summary

How does Avalyn Pharma compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalyn Pharma (AVLN) Competitors

AVLN vs. BLTE, LQDA, DFTX, AMRX, and MANE

How does Avalyn Pharma compare to Belite Bio?

Is AVLN or BLTE more profitable?

Do insiders and institutionals believe in AVLN or BLTE?

Which has preferable valuation and earnings, AVLN or BLTE?

Do analysts recommend AVLN or BLTE?

Does the media refer more to AVLN or BLTE?

Summary

How does Avalyn Pharma compare to Liquidia?

Which has stronger earnings & valuation, AVLN or LQDA?

Does the media prefer AVLN or LQDA?

Is AVLN or LQDA more profitable?

Do analysts rate AVLN or LQDA?

Do insiders and institutionals have more ownership in AVLN or LQDA?

Summary

How does Avalyn Pharma compare to Definium Therapeutics?

Do analysts rate DFTX or AVLN?

Which has preferable valuation & earnings, DFTX or AVLN?

Does the media refer more to DFTX or AVLN?

Is DFTX or AVLN more profitable?

Do insiders & institutionals have more ownership in DFTX or AVLN?

Summary

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Which has preferable valuation & earnings, AMRX or AVLN?

Does the media favor AMRX or AVLN?

Is AMRX or AVLN more profitable?

Do analysts rate AMRX or AVLN?

Do insiders and institutionals believe in AMRX or AVLN?

Summary

How does Avalyn Pharma compare to Veradermics?

Do analysts rate AVLN or MANE?

Does the media prefer AVLN or MANE?

Which has higher valuation and earnings, AVLN or MANE?

Is AVLN or MANE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools